Latest Health It Market News

Taiwanese tech manufacturer FSP Technology has converted its redeemable shares into 44.87 million ordinary shares in Harris Technology, deepening its strategic partnership as Harris expands in Australia's refurbished tech market.

Emyria has trained its first cohort of 31 clinicians in New South Wales, paving the way for its inaugural Sydney Empax clinic at Matilda Nepean, scheduled to open in Q3 2026.

Bhagwan Marine expects FY26 EBITDA between $44.5m and $46.5m, buoyed by Riverside Marine acquisition despite Middle East conflict causing project delays. The company highlights margin gains, disciplined costs, and rising recurring revenue as it advances integration and growth plans.

Evolution Mining has confirmed a fully franked dividend of AUD 0.20 per share for the half-year ending December 2025, alongside a Dividend Reinvestment Plan price set at AUD 14.4695 with no discount.

Island Pharmaceuticals reports a 213.8% increase in half-year loss to $4.81 million, driven by strategic acquisition and clinical development investments. The company advances its antiviral portfolio with Galidesivir and ISLA-101, supported by strong US regulatory engagement and a $9 million capital raise.

Audeara Limited reported a strong half-year revenue increase of 63.76% to $2.95 million, alongside a 57% reduction in net loss. However, the company flagged ongoing uncertainty about its ability to continue as a going concern.

Alcidion has secured regulatory approval for its AI-powered clinical tool in Australia and the UK, paving the way for commercial rollout in its largest markets. This milestone strengthens its position in healthcare technology and opens new sales avenues.

Shares of Apiam Animal Health Limited (ASX – AHX) have been suspended from trading following court approval of its acquisition by entities controlled by Adamantem Capital Fund II. This marks a significant ownership change for the animal health company.

Beetaloo Energy Australia Limited reported a solid cash position of $17.96 million at the end of December 2025, supported by $6.8 million in unused financing facilities. The company’s liquidity covers approximately 2.6 quarters of current cash outflows, positioning it well as it awaits the activation of a new $30 million infrastructure facility.

Summerset Group Holdings delivered a robust FY25 performance, achieving a 26% increase in total settlements driven by strong new sales and strategic expansion in Australia.

Nexsen Limited has initiated FDA engagement for its rapid Group B Streptococcus diagnostic sensor, aiming for expedited US market entry, while bolstering its leadership team and scientific credentials.

NTAW Holdings has secured an extension of its financial covenant waiver with Commonwealth Bank of Australia until March 2026, while continuing to reduce its borrowing facility.